You are currently viewing archive.bio.org. Head to our home page to check out our fresh new look!

BIO China: Zhangjiang Session

Biopharma Development in China and International Cooperation

Wednesday, October 12, 10:30am - 11:45am

China is one of the world's fastest growing emerging pharmaceutical markets. With its international position and influence on the rise, it has attracted a growing number of multinational pharmaceutical companies and research institutions to the country. An international cooperation has emerged between China and the worldwide bio-pharmaceutical industry, creating great opportunities, and challenges to be explored.

As such, the bio-pharmaceutical industry has been positioned as one of the national strategic and emerging industries, and the Chinese government is paying great attention to its developments. The government has established funds for research and development, aiming to give special support to the enterprises focused on innovation and participation in international cooperation; and to promote the bio-pharmaceutical industry with rapid and healthy development.

Zhangjiang Hi-Tech Park is one of the earliest National Hi-Tech Parks with the leading bio-pharmaceutical industry as its major industry. With Zhangjiang hosting dual development opportunities for the international and local bio-pharmaceutical industries, the concept of "innovation and integration" will positively undertake and promote the bio-pharmaceutical industry.

During this session, we will share the national strategic planning for the Chinese bio-pharmaceutical industry, the development of Zhangjiang Bio-Pharmaceutical industry cluster, and  successful international case studies from Zhangjiang.  We’ll also be exploring how to promote the global bio-pharmaceutical industry through enhanced international cooperation so that it may continue to flourish.

Moderator:

William R. Keller, Vice General Manager,  Shanghai Zhangjiang Biotech & Pharmaceutical Base Development Co. Ltd.

Panelists:

  • Mr. Yuliang Huang, CEO, Generon (Shanghai) Corporation
  • Dr. Douglas Khoo, Corporate VP Operations China & Indonesia, BPE, Boehringer Ingelheim
  • Mr. Jun Ren, CEO, Newsummit Biopharma Group
  • Richard Wang, Senior Director & Head of Operations, GSK R&D China
  • Mr. David Wilkinson, Global Product Director, AstraZeneca R&D Charnwood
  • Dr. Yichun Zhu, Dean of College Pharmacy, Institute of Drug R&D, Fudan University

Speech 1： Topic: “The registration and regulatory of China biological products and the overview of China pharmaceutical industry”   15 mins
Mrs He Bai, Division of Biological Products, Department of Drug Registration, SFDA


Speech 2： Topic: Innovation and Integrations-Development Strategy of Zhangjian Pharmaceutical Industry  15 mins
Mr. Lanzhong Wang, General Manager, Shanghai Zhangjiang Biotech & Pharmaceutical Base Development Co. Ltd


Speech 3： Topic: Chance and Challenge for MNEs’ in the area of new drug R&D in China  15 mins

Richard Wang, Senior Director and Head of Operations, GSK R&D China.

Conferences and Events: 
BIO Convention in China

BIO China: Business Development Panel

China – It's a Big Deal

Wednesday, October 12,  10:30am - 11:45am

M&A and drug development deals between Western and Chinese companies are on the rise.  This session will profile one of the most high-profile China-West collaborations of the past year.  The principal dealmakers from both companies will be on hand to discuss the deal’s development and will offer candid advice for companies pursuing China-West collaborations. 

Moderator:

  • Bernard Ng, Managing Director, Transaction Advisory Services (China), Ernst & Young

Panelists:

  • Frank K. Au, Chief Executive Officer, Cowen and Company Asia
  • Charles Hsu, PhD, MBA, Venture Partner, Mustang Ventures
  • Mark Lotter, CEO China Operations, SciClone Pharmaceuticals, Inc. and Former CEO, NovaMed
  • Gary Titus, Chief Financial Officer, SciClone Pharmaceuticals, Inc

Who's Who

 

Frank K. Au - Frank K. Au is the CEO of Cowen Latitude Asia, the wholly-owned Asia subsidiary of Cowen Group. Mr. Au is responsible for leading all aspects of Cowen’s businesses in Asia including capital markets, M&A and private placements. Prior to his appointment as CEO of Cowen Latitude Asia, Mr. Au was the President and co-founder of Latitude Capital Group, which was acquired by Cowen Group in 2008. He is based in the Firm's Hong Kong office and currently focuses on covering the alternative energy, consumer, health care, industrial, media and technology sectors in Asia.

Mr. Au is currently a Board Director of CDC Software and CDC Games, which are wholly-owned subsidiaries of CDC Corporation (NASDAQ).

Previously, Mr. Au was the Head of Media investment banking in Greater China for Lehman Brothers Asia. Mr. Au has extensive investment banking experience across all areas of corporate finance including equity and debt capital raising, as well as mergers and acquisition advisory having worked in both Lehman's New York and Hong Kong offices in the Technology, Telecom and Industrial/LBO Groups. He was also the President & Co-Founder of Pacific NetMarkets, an Internet technology incubator for companies in the Asia-Pacific region, which raised over US$25 million in venture capital financing.

Mr. Au holds an MBA from Harvard Business School and a BA in Economics/East Asian Studies from Columbia University.

Conferences and Events: 
BIO Convention in China

BIO China: Keynote Session with Qiyu Chen Chairman, Fosun Pharma

Qiyu Chen
Chairman, Fosun Pharma

Mr.Chen joined Fosun Pharma in 1994, he started his career firstly at the Research and Development Department of Shanghai RAAS Blood Product Co. Ltd.  After joining the Fosun Group, Mr.Chen has been working as Manager of the industry development department of Group, and Vice General Manager, Chief Financial Officer, Secretary to the Board, Executive Vice President and President of Fosun Pharma.

Mr.Chen is President of Shanghai BioPharmaceutics Industry Association, Director of Shanghai Genetics Society, Vice Chairman of the fourth council of China Medicinal Biotech Association, Member of the sixth session of Youth Union of Putuo District and Shanghai Government Procurement Evaluation Expert.

Mr.Chen awarded a Bachelor’s degree in genetic engineering in 1993 from Fudan University and an Executive Master of Business Administration in 2005 from China Europe International Business School.

Conferences and Events: 
BIO Convention in China

BIO China: Opening Ceremony

James C. Greenwood
President & CEO
Biotechnology Industry Organization

James C. Greenwood is President and CEO of the Biotechnology Industry Organization (BIO) in Washington, D.C., which represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the annual BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. Since his appointment in January of 2005, he has markedly enhanced the trade association’s capacity – increasing both its staff and budget by nearly fifty percent. BIO is now a world class advocacy organization playing a leading role in shaping public policy on a variety of fronts critical to the success of the biotechnology industry at the state and national levels as well as internationally. Mr. Greenwood represented Pennsylvania's Eighth District in the U.S. House of Representatives from January 1993 through January 2005. A senior member of the Energy and Commerce Committee, he was widely viewed as a leader on health care and the environment.

From 2001 to 2004, Mr. Greenwood served as Chairman of the Energy and Commerce Committee Subcommittee on Oversight and Investigation with oversight authority over issues in the full Committee's vast jurisdiction. He led hard-hitting investigations into corporate governance at Enron, Global Crossing and WorldCom; terrorist threats to our nation's infrastructure; and waste and fraud in federal government agencies. Prior to his election to Congress, Mr. Greenwood served six years in the Pennsylvania General Assembly (1981-86) and six years in the Pennsylvania Senate (1987-1992). Mr. Greenwood graduated from Dickinson College in 1973 with a BA in Sociology. From 1977 until 1980, he worked as a caseworker with abused and neglected children at the Bucks County Children and Youth Social Service Agency. Mr. Greenwood is married with three children and resides in Upper Makefield, Pennsylvania.

Conferences and Events: 
BIO Convention in China

BIO China 2011 Presenting Companies

Below please find the list of last year's presenting companies. Presenters at the BIO China 2012 event currently include: Biocrea GmbH, Chengdu Sen Nuo Wei Biotechnology Co., Genetech, Genor BioPharma Co., GlaxoSmithkline, HitGen, MedGenesis Therapeutix, Pharmaessentia Corp., Roche, Sanofi Pasteur, and SciClone Pharmaceuticals. The full list of presenting companies of 2012 will be updated shortly.

2011 Presenting Companies

Company News
Abbott Abbott
ABT | News
ABSize ABSize Inc.
Private | News
Allinky Biopharma Allinky Biopharma
Private | News
Alteogen Inc Alteogen Inc.
Private | News
Apexigen Inc. Apexigen Inc.
Private | News
Astex Astex Pharmaceuticals, Inc.
ASTX | News
Bayer Healthcare Bayer HealthCare Pharmaceuticals
BAY | News
Biocrea GmbH Biocrea GmbH
Private | News
Biomiga Diagnostics Biomiga Diagnostics
Private | News
Debiopharm Debiopharm Group
Private | News
Egen, Inc. EGEN, Inc.
Private | News
Frontier Biosciences Frontier BioSciences, Inc.
Private | News
Genentech Genentech
RHHBY | News

Genor BioPharma Logo
 Genor BioPharma Co., Ltd
Private | News

GlaxoSmithKline		 GlaxoSmithKline
GSK | News

Gloria Pharamceuticals

 Gloria Pharmaceuticals
SHE: 002437 | News
Golden Biotechnology Corp. Golden Biotechnology Corp.
Private | News
Humabs Humabs BioMed
Private | News
Impact Therapeutics IMPACT Therapeutics, Inc.
Private | News
Legacy Healthcare Legacy Healthcare
Private | News
Micron Inc. Micron Inc.
Private | News
Mycenax Biotech
 Mycenax Biotech Inc.
TPO: 4726 | News
NB Health Laboratory Co. Ltd. NB Health  Laboratory Co. Ltd
Private | News

Neurodyn

SIRC

Neurodyn & Shanghai Innovative
Research Center of Traditional
Chinese Medicine
Private | News
Neurotech USA, Inc.
Private | News
Novo Nordisk Novo Nordisk
NN Cph DKK | News
Pfizer Pfizer
PFE | News
Phage Pharmaceuticals

Phage Pharmaceuticals, Inc.
Private | News
Pharma Training Pharma Training Inc.
Private | News
Pharming Group

Pharming Group NV
AMS: PHARM | News
PhytoHealth PhytoHealth Corporation
TPE: 4108 | News
ProCell Therapeutics ProCell Therapeutics, Inc.
Private | News
Roche Roche
RHHBY | News
sanofi pasteur
 Sanofi Pasteur
SNY | News
Shenzhen Chipscreen Biosciences Shenzhen Chipscreen Biosciences Ltd.
Private | News
Thermostable Enzyme Laboratory Thermostable Enzyme Laboratory Co.,  Ltd.
Private | News
Transgenic TransGenic Inc.
Private | News
Upstream Infinity Upstream Infinity, Inc.
Private | News
WuXi Apptec WuXi AppTec
WX | News

 

Conferences and Events: 
BIO Convention in China

BIO Convention in China: Checklist for Presenting Companies

Companies selected to present will be notified via email. Once you confirm your presentation with us, you will receive the information listed below. All items must be completed. If you have not received an invitation, but would like to present, please fill out a short application online or contact Jennifer Fernandez at jfernandez@bio.org.

 

Checklist Item

Deadline

1. Did you receive an invitation to present at BIO Convention in China?

If yes, send an email to confirm your presentation to Jennifer Fernandez at jfernandez@bio.org. If not, please submit an application here. After which, you will be notified of your company's presentation status.

Space is limited.
Confirm your presentation as soon as possible.

2. Register for the conference and pay your presentation fee using the code provided in the confirmation email.

Your registration includes:

  • Access to BIO One-on-One Partnering SystemTM to schedule meetings with investors and potential partners.
  • Attendance at all plenary and business panels, therapeutic workshops, and company presentations.
  • Admission to networking lunches and receptions.

Early-Bird
Registration Deadline:  TBA

3. Create and publish your profile in the BIO One-on-One Partnering System.
 

Newly Registered attendees will be issued login information within two-five business days.

The BIO One-on-One Partnering System allows you to publish your company profile on the Partnering website, search the profiles of other attending companies, and schedule private meetings with potential partners and conference participants.

 

Profile Publication Deadline: TBA

5. Please provide contact information for your company presenter:

Name:
Title:
Email:
Onsite Phone Number:

Within Two Weeks of Your Confirmation

6. Review the Presentation Details & Guidelines

Prior to Conference

7. Book Your Stay at the hotel

Discount Deadline: TBA

8. Email Your Presentation to BIO Staff

All presentation materials must be sent to BIO staff prior to the start of the conference. Please note, presenters must also bring a back-up copy on flash-drive/USB to the event.

Please email your presentation to Jennifer Fernandez at jfernandez@bio.org.

To Send By

TBA

Additional Information

  • Specific time slots will be assigned in September.
  • Each company will have 25 minutes to present, although we recommend speaking for 20 minutes and reserving the remaining 5 for Q&A.
  • For all presentation-related questions, please visit our Presentation Details and Guidelines page.
  • You may also contact Customer Service at 866-365-5155 (US) or +1-202-962-6666 (International).
Conferences and Events: 
BIO Convention in China

BIO Convention in China: Presentation Details & Guidelines

Presentation Format:

  • All presentations are 25 minutes in length, including any Q&A. We highly suggest keeping the presentation to 20 minutes and reserving 5 minutes for Q&A.
  •  A company presentation should be given by one individual, typically a senior executive at the company.  
  •  All presenters at the BIO Convention in China are asked to prepare and submit their presentations in Microsoft PowerPoint for PC.
  •  All presentations must be sent to BIO staff prior to the event.
  •  Presentations must also be brought to the conference on flash cards, or USB ports.  
  •  Presentations cannot contain any video.
      

  Presentation Room:

  •  A dedicated computer operator will be assigned to each session room.
  •  There will be a BIO Staff Moderator in each presentation room to introduce all presenters.
  •  Presenters will not be permitted to hook a laptop to the digital projector in the presentation room.
  •  Microphones will be provided. 
  • Translation services will be provided for audience members.
  •  Please plan on arriving in your presentation room 10 minutes prior to the start of your presentation. 


Not yet presenting at BIO Convention in China? Learn more about the value of presenting at this event by clicking here.

Conferences and Events: 
BIO Convention in China

BIO Convention in China: Presenter Resource Center

Deadlines  |  Registration Instructions  |  Presenter Toolkit

The BIO Convention in China will feature company presentations by biotech and pharmaceutical companies. Presenting at this exclusive partnering forum provides companies with increased visibility in front of a global audience of biotech and pharmaceutical companies, all interested in cross-border business development alliances.

Presentations are scheduled in 25 minute slots. We highly suggest keeping the presentation to 20 minutes and reserving 5 minutes for Q&A. The typical audience features public and private equity investors, as well as research analysts, investment bankers and industry executives. 

Presenters can refer to this page for information regarding presentation logistics and submission, and press and media, among other topics. If your question is not addressed here, please contact us at 866-356-5155 (+1.202.962.6666 International) or email Sondra at sbehan@bio.org.

Upcoming Deadlines

Registration Instructions

Presentation Fee information can be found in the Registration pages below. Please pick your region to proceed.

  •  For North American, European and Non-China Asian participants click here. 
  •  For Chinese participants, click here.
     

Presenter & Media Toolkit

Conferences and Events: 
BIO Convention in China

BIO Convention in China: Company Presentation Information

The BIO Convention in China will feature company presentations by biotech and pharmaceutical companies. Presenting at this exclusive partnering forum provides companies with increased visibility in front of a global audience of biotech and pharmaceutical companies, all interested in cross-border business development alliances. Current confirmed companies include Hua Medicine, Genentech and Roche.

Increased Visibility = Increased Opportunity

  • Presenting companies receive increased visibility prior to the conference through BIO’s newsletters, website, and identification in the One-on-One Partnering™ system.
  • Presenting companies tend to schedule more one-on-one meetings than non-presenting companies.
  • Presenting at the BIO Convention in China places you in front of a larger audience, including companies who may have missed the opportunity to schedule a one-on-one meeting with you, as well as members of the press and media.

 

 

 

 

More Information

Conferences and Events: 
BIO Convention in China

BIO China 2011 Participating Companies

 

North American, European and Non-Chinese Asian Companies   Chinese Companies

Abbott
ABSize Inc.
Acorda Therapeutics, Inc.
Adamant Biomedical Investments AG
Aeterna Zentaris GmbH
Ajinomoto Co., Inc.
Alexandria Real Estate Equities, Inc.
Alkermes, Inc
Allinky Biopharma
Alteogen Inc.
Amgen Inc.
Anaphore, Inc.
Apexigen Inc.
Arena Pharmaeceuticals, Inc.
Ascletis Inc.
Ascendancy Healthcare, Inc.
AstraZeneca
AstraZeneca R&D Charnwood
AWEX
Bayer Animal Health GmbH
Bayer HealthCare
Baxter International Inc.
Becton Dickinson
Beijing Yudong Technology Development Ltd.
BG Consulting Pharma Development
BioAtla
BioBusiness International
Biocentury Publications, Inc.
BIOCOM
Biocrea Gmbh
Biogen Idec, Inc
Bioline
BioMarin Pharmaceutical, Inc
Biomedical Systems
Biopharm Insight
Biotech Development Conseils
BioView, Inc.
Biovision- the World Life Sciences Forum
BioWin
Boehringer Ingelheim BD & Licensing
Boehringer Ingelheim Biopharmaceuticals
Borden Ladner Gervais LLP
Bristol-Myers Squibb
Brunswick Law Firm
Bukwang Pharm. Co., Ltd.
Cambridge Enterprise Ltd.
Catalent Pharma Solutions
Centocor
Ceregene, Inc
Cerenis Therapeutics, SA
ChinaBio Today
Chong Kun Dang Pharmaceutical Corp.
Citigroup
Clifford Chance, LLP
Cooley LLP
Copenhagen Capacity
Coris Bioconcept
Cosmos Technical Center Co., Ltd.
Covington & Burling LLP
ChromaCon AG
CyBio AG
CzechInvest
Dainippon Sumitomo Pharma Co., Ltd.
Debiopharm SA
DesignMedix, Inc
Deutsche Bank Securities, Inc.
Develoment Program of Industrialization for Agricultural Bio
Dicerna Pharmaceuticals, Inc.
Dykema Gossett
Dynavax Technologies Corporation
Easton Associates, LLC
EBD Group
Edwards Angell Palmer & Dodge, LLP
EGEN, Inc.
Eli Lilly and Company
Elsevier Business Intelligence
Endoceutics
Enzo Life Sciences
Enzon Pharmaceuticals, Inc
Epitomics Inc
Ernst & Young
European Patent Office
FB Rice
FBRI
Ferring Pharmaceuticals Korea
Fidelity Investments
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Foundation for Biomedical Research and Innovation
Flavin Ventures
Fluor
Foundation For Biomedical Research And Innovation
Frontier BioSciences, Inc.
G3C Consulting Ltd
Genentech
GenePro Investment Corporation
Genoptix, Inc
GlaxoSmithKline
Global Health Ventures
Golden Biotechnology Corp.
Griffith University
Grünenthal GmbH
Hanall Biopharma Co., Ltd
Hanmi Pharmaceutical Co., Ltd.
Hanwha Chemical Cooperation
Health Ever Bio-Tech Co., Ltd.
Hoffman Eitle
Hong Kong Science and Technology
Hong Kong Zaotong Int Group Co., Ltd.
Parks Corp.
Humabs BioMed SA
Ibis Biosciences Inc.
Iddi
Ildong Pharmaceutical Co., Ltd.
Infinata, Inc.
Immunocore Ltd
IMS Health
Imperial Innovations
Industrial Research Limited
Innovent Biologics, Inc.
Institute for OneWorld Health
International Project/ Business Managment
inVentiv Health, Inc
Invest in Denmark
Invest In Skåne AB
Ipsen Biopharm Limited
IRE
Janssen-Cilag
Jefferies Hong Kong Limited
Johnson & Johnson Corporate Office of Science and Technology
Kilpatrick Townsend & Stockton LLP
Kinesis Pharma BV
Kolon Life Science, Inc.
Kroll Associates (asia) Limited
Lee & Hayes
Leerink Swann
Legacy Healthcare
Life Science Austria Vienna
Lonza Group Ltd.
Lonza Inc.
Lyon Captial, Inc.
Marks & Clerk
Marks & Clerk Singapore LLP
Maryland Department of Business & Economic Development
McDonnell Boehnen Hulbert & Berghoff LLP
Med Discovery SA
Medical Research Council Technology Ltd
Merck
Merck Serono SA
Meridigen Biotechnology
Micron, Inc.
Mitsubishi Corporation
Mitsui & Co. Global Investment
Molecularmd Corp
Monitor Group
MSD Australia
Mycenax Biotech Inc.
Nagoya University
National Defense University
NB Health Laboratory Co. Ltd.
Neurodyn Inc.
Neurotech USA, Inc.
NOAK NIG, LTD
Nomura Research & Advisory
Novartis Institutes for Biomedical Research
Novo Nordisk
OncoMed Pharmaceuticals, Inc
Osaka Pharmaceutical Manufacturers Association
Pappas Ventures
Pathway Therapeutics, Inc
Phage Pharmaceuticals, Inc.
Pharma Training, Inc.
Pharming Group N.V.
PhytoHealth Corporation
Pfizer
Potter Clarkson LLP
Presidio Pharmaceuticals
Pricespective, LLC
ProCell Therapeutics, Inc.
ProImmune Ltd
Promethera Biosciences
PROXY Laboratories BV
Quaestio Global Partners LLC
Rainmaker BI Inc.
Roche
Roche Pharma Division
Salix Pharmaceuticals, Inc.
SAMTOSH INTL NIG LTD
Sandoz Austria
Sanofi
Sanofi-Aventis, SA
Sanofi-Aventis K.K.
Sanofi Pasteur
Saxony Economic Development Corporation
Scandinavian Health Ltd.
Sciclone Pharmaceuticals
Scully, Scott, Murphy & Presser, PC
Servier
Simcere Pharmaceutical Group
Shire Pharmaceuticals, Inc
Shook, Hardy & Bacon, LLC
Squire, Sanders & Dempsey  LLP
SuperGen, Inc.
Sustineo Biotechnology
Synergion Biotechnologies, Inc
Taiwan Liposome Company, Ltd.
Takeda Pharmaceutical Company
Thermostable Enzyme Laboratory Co'; Ltd.
Torreya Partners, LLC
Trade Commissioner Service of Canada
TransGenic Inc.
TRPA
Ubivac
United States Patent and Trademark Office
University of Pennsylvania, Center for Technology Transfer
Upstream Infinity, Inc.
Uteron Pharma
WELBIO
Worldiscoveries

  

Abbott Shanghai
AllCells-Shanghai
AstraZeneca China
Baxter International Inc.- Shanghai
Bayer Healthcare Co. Ltd. - Beijing
Beijing Hanmi Pharm.
Biogen Idec Shanghai
BioLite, Inc.
BioWin Asia
Boehringer-Ingelheim - Shanghai
Bureau
Byte-online
Chengwei Capital
China Medical City
China Medical System Holdings Limited
Chubb Group of Insurance Companies
Clifford Chance, LLP
CN-KnowHow
Debiopharm S.A.
Dongguan Songshan Lake Sci. & Tech. Education
DSI Shanghai Office
Eli Lilly & Company - Shanghai
Encore BioPharma Partners
Ernst & Young, LLP
Ferring Pharmaceuticals Ltd.
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Fluor (China) Engineering & Construction
Fosun Group
Frontier Biotechnologies Co., Ltd.
G3C Consulting Ltd.
Genor BioPharma Co., Ltd.
Generon Corporation Ltd
GenScript USA. Inc
GlaxoSmithKline - Shanghai
Gloria Pharmaceuticals Co., Ltd.
HONGKONG ZAOTONG INT GROUP
Huabo Biopharm Co., Ltd.
Impact Therapeutics,Inc.
Innovent Biologics, Inc.
Janssen-Cilag
JiangSu Chia Tai TianQing Pharmaceutical Co. Ltd.
JS Biosciences
Livzon MABPharma, Inc.
Lonza, Inc.
Lyonbiopole
MARKS & CLERK
MerckSerono - Beijing
Morgan Stanley - Hong Kong
MSD China
NovaMed Pharmaceutical Co.
Pfizer Investment
Pioneer Pharma Co., Ltd.
Roche - Shanghai
Ropes & Gray, LLP
Sanofi-Aventis (China) Investment Co., Ltd.
Sanofi-Aventis China
Shangcheng & Partners
Shanghai biochip co. ltd.
Shanghai Biomabs Pharmaceuticals Co., Ltd.
Shanghai Center of Biomedicine Development
Shanghai ChemPartner Co., Ltd.
Shanghai Innovative Research Center of Traditional Chinese Medicine
Shanghai Medicilon Inc.
Shanghai Newsummit Pharmaceutical Group Co., Ltd
Shenzhen Chipscreen Biosciences, Ltd.
Sigma-Aldrich Corporation
Start Shanghai Company Limited
Swissnex China
Tianfu Life Science Park
The Mergermarket Group
TOT Biopharm Co., Ltd 
Trade Commissioner Service of Canada - Shanghai
Transpacific-IP
UCB Pharma SA
Viva Biotech Ltd.
VWR International
Wuhan National Bioindustry Base
WuXi AppTec Co., Ltd.
Xi'an Hi-tech Industries Development Zone
Xi'an-Janssen
ZJBPB
Conferences and Events: 
BIO Convention in China